Edit |   |
---|---|
Antigenic Specificity | PI3K p85 α, Human |
Clone | REAL589 |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | n/a |
Format | phycoerythrin (PE) conjugate |
Size | 200 µL |
Concentration | n/a |
Applications | MICS (MACSima Imaging Cyclic Staining), Immunohistochemistry, Immunofluorescence |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | PI3K p85 α Antibody, anti-human, PE, REAdye_lease™. Clone REAL589 is an antibody fragment derived from the full PI3K p85 alpha antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity. | Clone REAL589 recognizes the human Phosphoinositide 3-kinase (PI3K), also known as phosphatidylinositol 3-kinase which belongs to the family of related intracellular signal transducer enzymes. PI3Ks are involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking. Mutations in the gene promote the development of diseases such as allergies, heart diseases, inflammatory processes or cancer. The superfamily of PI3 Kinases consists of several enzymes, which are structurally closely related. | For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675). |
Immunogen | n/a |
Other Names | Phosphatidylinositol 3-kinase, PI3-kinase, anti-PI3K p85 alpha, PIK3R1, GRB1 |
Gene, Accession # | n/a |
Catalog # | 130-124-781 |
Price | $495 |
Order / More Info | PI3K p85 α, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Thorpe, L. M. et al. (2015) PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat. Rev. Cancer 15 (1): 7-24. | Kaneda, M. M. et al. (2016) PI3Kγ is a molecular switch that controls immune suppression. Nature 539 (7629): 437-442. | Rodgers, S. J. et al. (2017) Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases. Biosci. Rep. 37 (1): -BSR2016043. |